Company news
Vera Therapeutics, Inc. news in 2022
Vera Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
December 19, 2022
Vera Therapeutics to Present at Upcoming Investor Conferences
November 21, 2022
Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP
November 16, 2022
Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
November 8, 2022
Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidn...
November 4, 2022
Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week...
October 16, 2022
Vera Therapeutics to Present at Upcoming Conferences in September 2022
September 6, 2022
Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
August 9, 2022
Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference
August 3, 2022
Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
July 5, 2022
Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients
June 3, 2022
Vera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
June 1, 2022
Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress
May 19, 2022
Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
May 15, 2022
Vera Therapeutics to Present at Upcoming Conferences in May 2022
May 4, 2022
Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus
May 2, 2022
Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022
May 1, 2022
Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors
April 11, 2022
Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
March 23, 2022
Vera Therapeutics to Host BK Virus Webinar Featuring Stanley C. Jordan, M.D., World-Renowned Transplant Nephrologist and Pioneering Kidney Transplant Researcher
March 20, 2022
Vera Therapeutics to Host Business Update Call
March 16, 2022
Vera Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference
February 28, 2022
Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 13, 2022
Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis
January 17, 2022
Vera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022